Regeneron Pharmaceuticals: "Regeneron's a quandary. I've got to tell you, I expected sales to be better...I do prefer Eli Lilly."

LandBridge: "That's a winner. I would just hold on to it."

Get updates on what's happening in Boston to your inbox. Sign up for our News Headlines newsletter.

Click here to download Jim Cramer's Guide to Investing at no cost to help you build long-term wealth and invest smarter.

Sign up now for the CNBC Investing Club to follow Jim Cramer's every move in the market.

Disclaimer The CNBC Investing Club Charitable Trust holds shares of Eli Lilly.

Questions, comments, suggestions for the "Mad Money" website? [email protected]